Matthew Chivvis spoke to Bloomberg Law about a congressional push to let drug companies patent diagnostic tests and other biotech invention, which is rekindling a decade-old battle over whether the approach could spark innovation or stifle new treatments that could help patients.
According to Matthew, the proposed change in the law comes as "a new era of biotechnology" fuels more genetic discoveries that could have vast impact. The legislation "is trying to strike some sort of balance," Matthew said, adding: "I don't know whether it's the appropriate one."
Read the full article (subscription may be required).
Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
© Morrison & Foerster LLP. All rights reserved
